🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

.Johns Hopkins Gastroenterology & Hepatology Colorado course #DrRussCohen #IBD & MACE (major adverse cardiovascular event) 💎IBD🔥: ⬆️risk MI, AFib, DVT/PE 💎JAKi & MACE: 🔹ORAL: ⬆️risk of MACE (& CA) vs TNFi 🔹But: ✅Only in pts > age 65 ✅We know TNFi decrease MACE risk ✅Meta-analysis: No⬆️ MACE w JAKi

Practice changing!

Vedolizumab+ Upadacitinib vs Vedolizumab alone in mod-severe UC Even with the small sample size (n=61) one gets a sense seeing the data of the importance of the results #ECCO2025

Placental Transfer of Upadacitinib: much lower levels than mother at time of birth, but detectable. IBDJournal & CC360 Millie Long Sunanda Kane M.D. doi.org/10.1093/ibd/iz…

Another masterpiece by Anne-Louise Oliphant with this edition of the ACG Magazine! 🤩 #ProudToBeACG! Katie Dunleavy Jill Gaidos, MD Katie Hutchins, MD Mohammad Bilal, MD Loren G. Rabinowitz, MD Andrew Moon Joshua M. Steinberg, MD

Are you excited to graduate from #GI fellowship? READ ACG Magazine interviews of GI experts advice on how to thrive in your 1st job! Thank you! Amy Oxentenko MD Sumana Moole MD Andrew Moon Carl Kay, MD Mohammad Bilal, MD Joshua M. Steinberg, MD Katie Hutchins, MD Tauseef Ali MD, FACG AGAF FACP Loren G. Rabinowitz, MD

Excited to share the PIANO Helmsley Charitable Trust Global consensus patient education video: a universal recommendation for pregnant women with IBD! Thank you to all the GCC participants around the world! pianostudy.org/GCC_video/Main…

Friday 3/7/25 #DressinBlueDay #ColorectalCancerAwarenessMonth @WalterchanMD @IBDdocmaria @Francois1Fritz @DarwinConwell Mohammad Bilal, MD Rachel Issaka, MD, MAS Adjoa Anyane-Yeboa, MD MPH Fola May, MD PhD Darrell Gray, II, MD, MPH, FACG Brian Jacobson @feliceSchnoll David T. Rubin, MD Adam C. Ehrlich, MD, MPH, FACG Joshua M. Steinberg, MD Andrew Moon Allon Kahn, MD

*⃣*⃣*⃣ 4⃣5⃣ *⃣*⃣*⃣ ACG recommends #ColorectalCancerScreening starting at age 45 for average risk adults #Colonoscopy with polyp removal can prevent colorectal cancer Learn more about screening: gi.org/ColonCancer #ColorectalCancerAwarenessMonth #Gastroenterology

#MondayNightIBD Haley Mertens Katie Dunleavy Jalpa Devi Aimen Farooq Noor S. Syed, MD Mehak Bassi, MD Marcel Yibirin, MD, MPH Sanjeevani Tomar, MD Dheera Grover Samiksha Pandey, MD, MSc NEJM Adam Faye MD MS Adam C. Ehrlich, MD, MPH, FACG Brad Morganstern, MD Berkeley Limketkai Benjamin Clement, MD Ben Click Bharati Kochar 𝙱𝚎𝚗 𝙳𝚒𝚜𝚗𝚎𝚢 Bram Verstockt Dana Lukin MD, PhD Dr Dawn Beaulieu Michael J Rosen, MD, MSCI 4/ #Guselkumab in UC: #QUASAR ✅Classic RCT After IV induction Randomized withdrawal with 2 doses studied in maintenance 👇🏽 🔑Clinical remission= SF 0/1 ➕RB 0 + ES 0/1 w/o friability 🔑Endo improvement = ES 0/1 w/o friability 🔗The Lancet doi.org/10.1016/S0140-…

#MondayNightIBD Haley Mertens Katie Dunleavy Jalpa Devi Aimen Farooq Noor S. Syed, MD Mehak Bassi, MD Marcel Yibirin, MD, MPH Sanjeevani Tomar, MD Dheera Grover Samiksha Pandey, MD, MSc NEJM Adam Faye MD MS Adam C. Ehrlich, MD, MPH, FACG Brad Morganstern, MD Berkeley Limketkai Benjamin Clement, MD Ben Click Bharati Kochar 𝙱𝚎𝚗 𝙳𝚒𝚜𝚗𝚎𝚢 Bram Verstockt Dana Lukin MD, PhD Dr Dawn Beaulieu Michael J Rosen, MD, MSCI The Lancet Freddy Caldera, DO, PhD Jordan Axelrad, MD, MPH Meena Bewtra Harry Thomas Mohamad El Zein MD, MPH  د. محمد عبدالله شهاب Daniel J. Stein Joshua M. Steinberg, MD Eric Benchimol Neilanjan Nandi, MD, FACG, AGAF, FCCF, FACP Harry Sokol Edward Loftus Tauseef Ali MD, FACG AGAF FACP David Fudman, MD Frank I Scott, MD MSCE FB IBDologist… Fabio Teixeira Fabi An E. Puentes M. carlos rettally Sara Horst MD, MPH, FACG Amar S. Naik, MD Beatriz Gros Miguel Regueiro ignacio catalan Lumír Kunovský 11/ Gus in Crohns 📊Clinical Remission 🗓️Post-induction wk12: large delta for both bio-exposed & naive 🗓️wk52: 60% vs 17% w similar results bio-naive & exposed 🤔Similar response w higher/lower SC maintenance dose 🔦Endo response: delta (44) w higher SC dose > (37) w lower dose

Tremfya is FDA approved for Crohn's disease! This has both IV (200 mg) and subq (400 mg) induction loading dose options followed by subq maintenance dose (100 mg or 200 mg). #GITwitter #IBD jnj.com/media-center/p…

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease jnj.com/media-center/p…

‼️ Denver #IBD community: join us for a special Crohn's & Colitis Foundation patient & caregiver education event on April 1st. We’ll have a fantastic panel to discuss topics including new IBD therapies, diet/nutrition, mental health + pt perspectives. Register here: crohnscolitisfoundation.org/myibdlearning/…

#DDW2025 SQ induction Guselkumab in UC #ASTRO Millie Long 🔺GUS 400mg SC q4w x3 vs placebo -> GUS 100mg SC q8w or 200mg SC q4w vs placebo 🔺Wk12 Gus vs placebo ✔️ClinRem 27% vs 6% ✔️EndoImprov 37% vs 13% ✔️ClinResp 65% vs 34% ✔️HEMI 30% vs 11% ⚠️🟰QUASAR IV induction data !

Yes as good as if not numerically better than IV

#DDW2025 TY for sharing Pauli Great to see RCT data that confirms my clinical impression/ experience that adding Vedo to partial responder to UPA -> remission in refractory mod-severe UC Joshua M. Steinberg, MD Oriana M. Damas, MD MSCTI Bincy Abraham, MD, MS Parakkal Deepak MD, MS, FACG

Start planning for #ACG2025! ☀️🏜️🌵 ✈️ Here we come AZ!! 🗓️Oct 24–29, 2025 💵ACG member? Annual Sci Mtg reg is FREE! 🤩 ➡️ acgmeetings.gi.org ⬅️ 👋See you all there!👋 🤓Come for the learning 💥Witness the #BOOM!